Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Other Non-Current Assets data on file, last reported at $26.2 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 2.65% year-over-year to $26.2 million in Q1 2026; TTM through Mar 2026 was $26.2 million, a 2.65% decrease from a year earlier, with the FY2025 full-year figure at $25.9 million, up 4.84% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $26.2 million, up from $25.9 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for DNLI reached as high as $50.6 million in Q2 2024 and fell as low as $11.1 million in Q3 2023.
• Historically, Other Non-Current Assets has averaged $23.0 million across 5 years, with a median of $23.0 million in 2025.
• Across the five-year window, Other Non-Current Assets soared 326.71% in 2022 and slumped 54.58% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $13.4 million in 2022, then surged by 35.41% to $18.1 million in 2023, then jumped by 36.37% to $24.7 million in 2024, then gained by 4.84% to $25.9 million in 2025, then rose by 1.08% to $26.2 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $26.2 million in Q1 2026, $25.9 million in Q4 2025, and $25.1 million in Q3 2025.